Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

VBI Vaccines

DB:LO91
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LO91
DB
$180M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The last earnings update was 32 days ago. More info.


Add to Portfolio Compare Print
  • VBI Vaccines has significant price volatility in the past 3 months.
LO91 Share Price and Events
7 Day Returns
1.4%
DB:LO91
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-52.5%
DB:LO91
-13.2%
DE Biotechs
-20.9%
DE Market
LO91 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
VBI Vaccines (LO91) 1.4% -31.2% -36.9% -52.5% -83.3% -
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • LO91 underperformed the Biotechs industry which returned -13.2% over the past year.
  • LO91 underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
LO91
Industry
5yr Volatility vs Market
Related Companies

Value

 Is VBI Vaccines undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for VBI Vaccines. This is due to cash flow or dividend data being unavailable. The share price is €0.8262.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for VBI Vaccines's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are VBI Vaccines's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:LO91 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.46
NasdaqCM:VBIV Share Price ** NasdaqCM (2020-04-03) in USD $1.01
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of VBI Vaccines.

DB:LO91 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:VBIV Share Price ÷ EPS (both in USD)

= 1.01 ÷ -0.46

-2.2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • VBI Vaccines is loss making, we can't compare its value to the Europe Biotechs industry average.
  • VBI Vaccines is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does VBI Vaccines's expected growth come at a high price?
Raw Data
DB:LO91 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.2x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
11.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for VBI Vaccines, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on VBI Vaccines's assets?
Raw Data
DB:LO91 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.50
NasdaqCM:VBIV Share Price * NasdaqCM (2020-04-03) in USD $1.01
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:LO91 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:VBIV Share Price ÷ Book Value per Share (both in USD)

= 1.01 ÷ 0.50

2.04x

* Primary Listing of VBI Vaccines.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • VBI Vaccines is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess VBI Vaccines's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. VBI Vaccines has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is VBI Vaccines expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is VBI Vaccines expected to grow at an attractive rate?
  • Unable to compare VBI Vaccines's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare VBI Vaccines's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • VBI Vaccines's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:LO91 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:LO91 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 11.5%
DB:LO91 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 46.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:LO91 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:LO91 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 42 -20 -27 3
2023-12-31 23 -30 -37 3
2022-12-31 29 -46 -49 3
2021-12-31 5 -42 -46 3
2020-12-31 3 -41 -49 3
2020-04-06
DB:LO91 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 2 -49 -55
2019-09-30 4 -48 -63
2019-06-30 4 -47 -62
2019-03-31 4 -51 -66
2018-12-31 3 -46 -64
2018-09-30 1 -47 -56
2018-06-30 1 -40 -50
2018-03-31 1 -32 -43
2017-12-31 1 -31 -39
2017-09-30 1 -30 -36
2017-06-30 1 -28 -33
2017-03-31 1 -25 -31

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • VBI Vaccines is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • VBI Vaccines's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:LO91 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from VBI Vaccines Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LO91 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.12 -0.04 -0.20 3.00
2023-12-31 -0.17 -0.08 -0.23 3.00
2022-12-31 -0.24 -0.14 -0.33 2.00
2021-12-31 -0.23 -0.21 -0.25 3.00
2020-12-31 -0.26 -0.21 -0.32 3.00
2020-04-06
DB:LO91 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.46
2019-09-30 -0.69
2019-06-30 -0.76
2019-03-31 -0.89
2018-12-31 -0.97
2018-09-30 -0.90
2018-06-30 -0.89
2018-03-31 -0.85
2017-12-31 -0.88
2017-09-30 -0.91
2017-06-30 -0.87
2017-03-31 -0.87

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if VBI Vaccines will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess VBI Vaccines's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
VBI Vaccines has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has VBI Vaccines performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare VBI Vaccines's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • VBI Vaccines does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare VBI Vaccines's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare VBI Vaccines's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
VBI Vaccines's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from VBI Vaccines Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:LO91 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 2.22 -54.81 14.09 26.33
2019-09-30 4.33 -63.19 19.88 32.07
2019-06-30 3.94 -62.39 20.53 37.18
2019-03-31 3.54 -65.96 21.05 40.73
2018-12-31 3.36 -63.60 20.51 38.47
2018-09-30 0.87 -55.89 14.63 34.92
2018-06-30 0.81 -50.33 13.35 29.62
2018-03-31 0.92 -42.61 12.41 23.23
2017-12-31 0.87 -39.00 12.03 20.92
2017-09-30 0.80 -35.86 9.28 18.61
2017-06-30 0.89 -33.36 9.94 16.77
2017-03-31 0.63 -30.76 10.31 14.37
2016-12-31 0.55 -23.21 9.24 9.97
2016-09-30 0.40 -18.97 8.51 6.03
2016-06-30 0.22 -30.82 8.10 16.27
2016-03-31 0.58 -25.44 5.95 14.26
2015-12-31 0.96 -26.19 4.71 0.62
2015-09-30 2.10 -23.04 5.21 13.95
2015-06-30 2.38 -6.22 3.12 0.60
2015-03-31 2.39 -6.46 2.77 0.63
2014-12-31 2.87 -5.67 2.73 0.63
2013-12-31 1.66 -8.86 2.85 0.61

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if VBI Vaccines has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if VBI Vaccines has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if VBI Vaccines improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess VBI Vaccines's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
VBI Vaccines has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is VBI Vaccines's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up VBI Vaccines's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • VBI Vaccines is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • VBI Vaccines's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of VBI Vaccines's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from VBI Vaccines Company Filings, last reported 3 months ago.

DB:LO91 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 88.26 14.85 44.21
2019-09-30 97.22 14.60 53.02
2019-06-30 76.25 14.36 30.08
2019-03-31 86.70 14.10 43.31
2018-12-31 98.13 14.03 59.27
2018-09-30 77.13 13.68 25.99
2018-06-30 89.80 13.73 41.13
2018-03-31 106.46 13.44 58.09
2017-12-31 119.79 13.14 67.69
2017-09-30 62.97 12.84 10.05
2017-06-30 69.36 12.54 15.64
2017-03-31 75.86 12.24 23.51
2016-12-31 83.73 11.96 32.28
2016-09-30 79.50 2.00 16.72
2016-06-30 86.54 2.21 21.81
2016-03-31 10.42 0.00 10.96
2015-12-31 12.19 0.00 12.48
2015-09-30 29.42 0.00 16.01
2015-06-30 -12.20 11.74 0.02
2015-03-31 -10.76 10.81 0.30
2014-12-31 -9.41 9.78 0.52
2013-12-31 -30.62 28.04 0.03
  • VBI Vaccines's level of debt (16.8%) compared to net worth is satisfactory (less than 40%).
  • VBI Vaccines had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • VBI Vaccines has less than a year of cash runway based on current free cash flow.
  • VBI Vaccines has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 38.7% each year.
X
Financial health checks
We assess VBI Vaccines's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. VBI Vaccines has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is VBI Vaccines's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from VBI Vaccines dividends.
If you bought €2,000 of VBI Vaccines shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate VBI Vaccines's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate VBI Vaccines's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:LO91 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:LO91 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-06

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as VBI Vaccines has not reported any payouts.
  • Unable to verify if VBI Vaccines's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of VBI Vaccines's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as VBI Vaccines has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess VBI Vaccines's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can VBI Vaccines afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. VBI Vaccines has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of VBI Vaccines's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jeff Baxter
COMPENSATION $1,492,269
AGE 58
TENURE AS CEO 3.9 years
CEO Bio

Mr. Jeffrey R. Baxter, FCMA, also known as Jeff has been the Chief Executive Officer and President of VBI Vaccines Inc. since 2009. Mr. Baxter has been the Chief Executive Officer and President of VBI DE since July 2014. He has been the Chief Executive Officer of VBI US since September 2009. He has more than two decades of outstanding success in the biotechnology and pharmaceuticals industries. In his 19 years of pharma experience, he has experience ranging from management operations to finance and business development and venture capital and has held line management roles in commercial, manufacturing, information technology and the office of the Chief Executive Officer. He served as a Managing Partner at The Column Group LLC. He played a pivotal role in the creation of Immune Design Corp. Mr. Baxter served as Senior Vice President of Research & Development and Finance & Operations, Vice President of Competitive Excellence and Head of Finance, Worldwide Manufacturing & Supply and Chairman of Research and Development Operating Board/Senior Vice President of R&D Finance and Operations at GlaxoSmithKline plc (GSK) until July 2006. He served at Unilever plc and British American Tobacco Plc. Mr. Baxter’s most recent position from 2002 to 2006 in research and development included responsibility for finance, pipeline resource planning and allocation, business development deal structuring and SROne. He also chaired GSK’s Research and Development Operating Board. He has been a Director of VBI Vaccines Inc. since 2009, VBI DE since July 2014 and VBI US since September 2009. He has been a Non Executive Director of ChromaDex Corporation since April 16, 2015. He has been a Director of SciVac Therapeutics Inc since May 6, 2016. He is a Fellow of the Chartered Institute of Management Accountants (FCMA). Mr. Baxter was educated at Thames Valley University, University of Bradford Management School and London Business School.

CEO Compensation
  • Jeff's compensation has increased whilst company is loss making.
  • Jeff's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the VBI Vaccines management team in years:

2.8
Average Tenure
54
Average Age
  • The tenure for the VBI Vaccines management team is about average.
Management Team

Jeff Baxter

TITLE
President
COMPENSATION
$1M
AGE
58
TENURE
3.9 yrs

David Anderson

TITLE
Chief Scientific Officer
COMPENSATION
$922K
AGE
49
TENURE
3.9 yrs

Francisco Diaz-Mitoma

TITLE
Chief Medical Officer
COMPENSATION
$957K
AGE
64
TENURE
4.2 yrs

Chris McNulty

TITLE
CFO, Head of Business Development & Director
AGE
42
TENURE
1.7 yrs

Nicole Anderson

TITLE
Director of Corporate Communications & Investor Relations

Athena Kartsaklis

TITLE
Senior VP of Finance
AGE
54
TENURE
2.6 yrs

Nell Beattie

TITLE
Chief Business Officer
AGE
31
TENURE
2.6 yrs

Avi Mazaltov

TITLE
Global Head of Manufacturing & GM of SciVac
AGE
57
TENURE
3.1 yrs

Misha Nossov

TITLE
Senior Vice President of Market Access & Commercial
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the VBI Vaccines board of directors in years:

2.3
Average Tenure
63.5
Average Age
  • The average tenure for the VBI Vaccines board of directors is less than 3 years, this suggests a new board.
Board of Directors

Steve Gillis

TITLE
Chairman
COMPENSATION
$493K
AGE
66
TENURE
3.9 yrs

Jeff Baxter

TITLE
President
COMPENSATION
$1M
AGE
58
TENURE
3.9 yrs

Chris McNulty

TITLE
CFO, Head of Business Development & Director
AGE
42
TENURE
1 yrs

Blaine McKee

TITLE
Independent Director
AGE
54
TENURE
1.3 yrs

Joanne Cordeiro

TITLE
Independent Director
AGE
61
TENURE
1 yrs

Michel De Wilde

TITLE
Independent Director
COMPENSATION
$365K
AGE
70
TENURE
3.9 yrs

Stanley Plotkin

TITLE
Member of Scientific Advisory Board
AGE
86

Denis Burger

TITLE
Member of Scientific Advisory Board
AGE
75

Robert Pass

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs

Adam Finn

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
24. Jan 20 Buy Arch Venture Partners, L.P. Company 19. Sep 19 19. Sep 19 10,000,000 €0.45 €4,524,500
07. Oct 19 Buy F. Diaz-Mitoma Medicine Professional Corporation Company 04. Oct 19 04. Oct 19 40,000 €0.46 €18,220
07. Oct 19 Buy Francisco Diaz-Mitoma Individual 30. Sep 19 30. Sep 19 14,500 €0.46 €6,649
01. Oct 19 Buy Christopher McNulty Individual 01. Oct 19 01. Oct 19 12,000 €0.43 €5,194
01. Oct 19 Buy Nell Beattie Individual 01. Oct 19 01. Oct 19 10,000 €0.44 €4,413
30. Sep 19 Buy Jeffrey Baxter Individual 30. Sep 19 30. Sep 19 150,000 €0.46 €69,195
24. Sep 19 Buy Perceptive Advisors LLC Company 23. Sep 19 23. Sep 19 20,000,000 €0.45 €9,094,000
01. Jul 19 Buy F. Diaz-Mitoma Medicine Professional Corporation Company 27. Jun 19 27. Jun 19 8,000 €0.94 €7,531
20. Jun 19 Buy Perceptive Advisors LLC Company 18. Jun 19 18. Jun 19 1,000,000 €0.58 €580,255
20. Jun 19 Buy F. Diaz-Mitoma Medicine Professional Corporation Company 20. Jun 19 20. Jun 19 10,000 €0.69 €6,919
20. Jun 19 Buy F. Diaz-Mitoma Medicine Professional Corporation Company 20. Jun 19 20. Jun 19 42,000 €0.79 €33,156
20. Jun 19 Buy F. Diaz-Mitoma Medicine Professional Corporation Company 20. Jun 19 20. Jun 19 52,000 €0.79 €40,075
19. Jun 19 Buy Nell Beattie Individual 19. Jun 19 19. Jun 19 8,000 €0.66 €5,247
19. Jun 19 Buy Jeffrey Baxter Individual 19. Jun 19 19. Jun 19 144,000 €0.65 €93,907
18. Jun 19 Buy Perceptive Advisors LLC Company 17. Jun 19 17. Jun 19 1,000,000 €0.55 €550,144
X
Management checks
We assess VBI Vaccines's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. VBI Vaccines has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company’s enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Details
Name: VBI Vaccines Inc.
LO91
Exchange: DB
Founded:
$166,878,863
178,257,199
Website: http://www.vbivaccines.com
Address: VBI Vaccines Inc.
222 Third Street,
Suite 2241,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM VBIV Ordinary Shares Nasdaq Capital Market US USD 29. Dec 2009
DB LO91 Ordinary Shares Deutsche Boerse AG DE EUR 29. Dec 2009
DB LO91 COM NPV (POST REV SPLIT) Deutsche Boerse AG DE EUR 06. Apr 2020
Number of employees
Current staff
Staff numbers
124
VBI Vaccines employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 00:55
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/04/01
Last earnings filing: 2020/03/05
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.